Search results for: Competition
Filter search results
Combination Therapies: A Step Forward to the Value Attribution Problem
4 January 2023
…VP of Global Value and Access at Amgen, discussed the four policy domains that need to be addressed to improve access to CTs: the incentive problem, the implementation problem, competition…
The Impact of Biosimilars on Markets
24 May 2010
…has enacted the Biologics Price Competition and Innovation Act of 2009 (a subtitle of the Patient Protection and Affordable Health Care Act signed into law in March 2010). Among other things,…
Hospital Concentration and Patient Health Gain
21 September 2014, 11:00pm
Health care reforms in England during the last decade have been influenced by the idea that encouraging competition between hospitals, but with prices fixed nationally, will increase the quality of…
Biosimilars: Modelling the Evolution of the Market
16 June 2010
…should begin to rise as competition is based more on price. The OHE findings on price trajectories and price discounting strategies vary from other models by starting with transaction price,…
Estimating US Savings from Biosimilars
13 July 2010
…Health. Since the seminar, the US has passed the Biologics Price Competition and Innovation Act of 2009, a subtitle of the Patient Protection and Affordable Care Act that was signed into law…
The Impact of Science Policy Research
27 October 2010
Science, technology and innovation (STI) are gaining even greater importance with globalisation and international competition. The benefits STI provides, however, also carry risks and social costs. Science policy research is…
Should Drug Prices Differ by Indication? The Debate on Indication-based Pricing
11 May 2018
…a move to a multiple-price system. A number of US payers see the potential for IBP to increase price competition in some indications, and NHS England has used contracting by…
OHE at HESG, AES and PROMs Summer 2018
15 June 2018
…for different health care services. Oral presentation: R&D, Competition and Diffusion of Innovation in the EU: The Case of Direct Acting Antivirals (DAAs) for Hepatitis C [Wednesday, 15:15-16:45,…
OHE Achievements in 2018
27 December 2018
…The key finding is that these models can lead to more competition and so better value for money for payers. The other, funded by Cancer Research UK, entitled making outcomes-based…